Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
Cervical cancer is the leading cause of cancer deaths for women low- and middle-income countries, including Botswana, where 75 percent of cervical cancer patients suffer from advanced forms of the disease.
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
A team of researchers at the Research Institute of the McGill University Health Centre has found an epigenetic modification that might be the cause of 15% of adult cancers of the throat linked to alcohol and tobacco use.
Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.
Researchers have found that people with advanced head and neck squamous cell carcinoma and the KRAS-variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation.
A new study suggests the possibility of predicting at its earliest stages when a type of head and neck cancer will come back.
A number of genetic variants associated with susceptibility to oral cavity and pharyngeal cancer have been described in an international study published in the journal Nature Genetics.
Results of the largest Canadian clinical trial to date comparing standard treatment for locally advanced squamous cell head and neck cancer with an experimental treatment, did not show the new treatment is superior.
Patients wait an average of four months before seeking a cancer diagnosis, researchers report at the ESMO ASIA 2016 Congress in Singapore.
Researchers at the University of Cincinnati have discovered that an ion channel, active within T cells (white blood cells), could be targeted to reduce the growth of head and neck cancers.
When Kerstin Stenson, MD, describes the innovative technique she is helping develop to fight cancer, it seems like she's describing a Tom Clancy military espionage novel.
A study led by UCLA researchers found that in people with breathing difficulties caused by phrenic nerve injury surgical reconstruction of the nerve can lead to significant improvement in breathing and an increase in regular physical activities.
Sanford Health has opened another clinical trial exploring the power of the body's immune system to fight cancer.
A nationwide study of head and neck cancers in France has revealed that the true burden of the disease is underestimated by at least one-third, and that head and neck cancers carry a very high risk of secondary primary cancers, according to two presentations at the ESMO 2016 Congress in Copenhagen.
The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen.
For many patients, the uncertainty and stress that can come with cancer treatment is compounded by what is now known as "financial toxicity," the anxiety and distress that follow health care and medication expenses, often compounded by reduced ability to work.
Radiation therapy is the main treatment modality in the management of head and neck cancer.
When it comes to cancer-causing viruses like human papillomavirus, or HPV, researchers are continuing to find that infection with one strain may be better than another.
The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease.
Uveal melanoma (UM) is the second most common type of skin cancer. Approximately 50 percent of patients will develop metastasis or spread of their cancer, most commonly to the liver.